thepeptidecatalog

Science-first peptide research, pricing tools, and visual pathway guides.
Learn peptides. Compare vendors. Train smarter. Age better.

[thepeptidecatalog @peptidecatalog]

Made a short breaking down exactly how BPC-157's mechanisms mirror Wolverine's healing factor. The science is wild:

https://t.co/fsVy3BYyNp

(Though unlike Logan, you still need to source it legally 😉)

[thepeptidecatalog @peptidecatalog]

Full P-21 breakdown — neurogenesis and tau claims sorted by evidence source, and why its clean record still is not human proof: https://t.co/zr2fdZjOI0

[thepeptidecatalog @peptidecatalog]

P-21 is the nootropic peptide worth knowing about for one reason its hype-cousin Dihexa lacks: a clean literature. Dihexas foundational mechanism papers were retracted in 2025 for image manipulation. P-21s record carries no retractions or integrity flags. (1/3)

[thepeptidecatalog @peptidecatalog]

The catch: clean but entirely preclinical, and mostly from one originating lab. No human trials, no human PK, no established dose. So "no retractions" beats Dihexa, but it is still rodent data — not proof it works in healthy people. Research-context only. (3/3)

[thepeptidecatalog @peptidecatalog]

P-21 (P021) is a CNTF-derived tetrapeptide from Iqbals lab. In rodents it raised BDNF, drove hippocampal neurogenesis, and reduced tau — even improved survival in an Alzheimers mouse model (Kazim 2014, PMID 25046994). Consistent direction across studies. (2/3)

[thepeptidecatalog @peptidecatalog]

Full PDA breakdown — claimed benefits ranked by what evidence actually exists, and what it can not claim: https://t.co/mCNumODGf4

[thepeptidecatalog @peptidecatalog]

PDA (pentadeca arginate) is sold as an "upgraded, more stable BPC-157." Worth knowing before you buy: a PubMed search for "pentadeca arginate" returns zero peer-reviewed studies. None. (1/3)

[thepeptidecatalog @peptidecatalog]

The "more stable" pitch may be real chemistry — arginine salts can improve solubility — but no published study shows it improves healing outcomes vs the acetate form. "Upgraded BPC-157" is a marketing frame, not an evidence one. Research-context only. (3/3)

[thepeptidecatalog @peptidecatalog]

PDA is the exact same 15-amino-acid sequence as BPC-157 (GEPPPGKPADDAGLV), just paired with an arginine counterion instead of acetate. Every benefit claim is borrowed BPC-157 research — which is itself mostly rodent and cell-culture. (2/3)

[thepeptidecatalog @peptidecatalog]

@curoyou Exactly. The receptor mix is the design spec, not a power level. GLP-1 = appetite. +GIP = insulin sensitivity and amplified satiety. +glucagon = energy expenditure and hepatic fat oxidation. Reta adds the third lever, which is why the liver-fat data looks different.

[thepeptidecatalog @peptidecatalog]

Retatrutide is the first triple agonist in the GLP-1 class. Semaglutide hits one receptor (GLP-1). Tirzepatide hits two (GLP-1 + GIP). Retatrutide hits three -- it adds glucagon. That third receptor is doing most of the heavy lifting. (1/3)

[thepeptidecatalog @peptidecatalog]

Full writeup with the numbers and what to do about it: https://t.co/Uc7iHvVyAV

[thepeptidecatalog @peptidecatalog]

New data from ENDO 2026: people on GLP-1s lost weight but also moved less.

A Fitbit cohort (753 patients, All of Us program) found daily steps dropped a mean of 560/day after starting semaglutide- or tirzepatide-class drugs. From 5,047 to 4,487. (1/4)

[thepeptidecatalog @peptidecatalog]

The lever you control: keep activity up during the cut. Resistance training + protein are the trial-supported foundation. Community stacks often add GH secretagogues (tesamorelin, ipamorelin/CJC) for lean-tissue support.

Full breakdown below. (4/4)

[thepeptidecatalog @peptidecatalog]

Why it matters: published GLP-1 trials already show a big chunk of weight lost is lean mass, not just fat. Less movement + appetite suppression compounds that.

It is a conference abstract, not peer-reviewed yet, so read it as a signal not settled. (3/4)

[thepeptidecatalog @peptidecatalog]

Full Selank breakdown -- the anxiety trial data, GABA/BDNF mechanism, immune effects, and how it pairs with Semax: https://t.co/B0qi9PVnDG

[thepeptidecatalog @peptidecatalog]

Selank is the peptide that gets mentioned alongside Semax but does the opposite job. Semax is cognition-first. Selank is anxiety-first. It is a synthetic relative of tuftsin, developed in Russia, where it is an approved nasal spray for generalized anxiety. (1/3)

[thepeptidecatalog @peptidecatalog]

Why people stack it with Semax: different pathways, complementary jobs. Semax for stimulating focus, Selank for the calm/anti-anxiety side. Caveat: most of the human data is Russian-language and the Western RCT base is thin. Promising, not proven by Western standards. (3/3)

[thepeptidecatalog @peptidecatalog]

The notable finding: a human trial reported anxiolytic effect comparable to a standard reference anxiety medication -- but without the sedation, tolerance, or dependence that class is known for. The proposed route is GABA modulation plus BDNF upregulation. (2/3)

[thepeptidecatalog @peptidecatalog]

Full TB-500 breakdown -- 7 benefits ranked by actual evidence quality, the 61% wound-healing data, and where the human research really stands: https://t.co/u2vD1V7sqZ

[thepeptidecatalog @peptidecatalog]

Everyone uses TB-500 for muscle and joint recovery. But the strongest published evidence is somewhere most people never look: wound healing. Thymosin beta-4 increased re-epithelialization by up to 61% versus controls in dermal wound models. (1/3)

[thepeptidecatalog @peptidecatalog]

Honest caveat: most of the published work uses the full thymosin beta-4 molecule, not TB-500 specifically, and much of it is preclinical. The healing data is real but the human RCT base is thinner than the gym-bro reputation suggests. Worth knowing before you run it. (3/3)

[thepeptidecatalog @peptidecatalog]

The proposed mechanism is actin binding. TB-500 is a short fragment of thymosin beta-4 that carries the active region tied to cell migration -- the step that lets new tissue move into a healing site. That same signaling shows up in tendon and cardiac repair research too. (2/3)